NTRK gene fusions occur when a part of the NTRK gene fuses with another gene, leading to the production of TRK fusion proteins that can drive cancer development. These fusions are relatively rare but have been identified in various tumor types, including sarcoma, thyroid cancer, and breast cancer. The ability of entrectinib to target these fusions allows it to be effective across multiple cancer types with this genetic alteration.
